🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

94 results for “Novo Nordisk A/S” Clear

  1. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    Novo Nordisk A/S

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  2. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    Novo Nordisk A/S

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  3. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    Novo Nordisk A/S

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  4. Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity

    Novo Nordisk A/S

    Overweight and obesity

    phase 3 other active

    1 trial

  5. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    Novo Nordisk A/S

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  6. Etavopivat A 200 mg

    Novo Nordisk A/S

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  7. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    Novo Nordisk A/S

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  8. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  9. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    Novo Nordisk A/S

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  10. Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  11. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    Novo Nordisk A/S

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    Novo Nordisk A/S

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  13. NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  14. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    Novo Nordisk A/S

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  15. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    Novo Nordisk A/S

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  16. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    Novo Nordisk A/S

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  17. NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  18. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    Novo Nordisk A/S

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  19. Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

    Novo Nordisk A/S

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  20. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  21. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    Novo Nordisk A/S

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  22. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  23. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  24. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources